N040 Stock Chart & Stats
€3.20
€0.00(0.00%)
At close: 4:00 PM EDT
€3.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.20 - €7.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.26M
Enterprise Value-€18.63M
Total Cash (Recent Filing)€19.39M
Total Debt (Recent Filing)€667.94K
Price to Earnings (P/E)―
Beta-1.70
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding4,161,971
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Oncology IPThe European composition-of-matter patent strengthens protection for NUC-7738 across a major market and adds to NuCana’s broad issued-patent estate. Durable intellectual property can support clinical investment, preserve differentiation, and improve potential commercialization prospects if development succeeds.
Low Balance-sheet LeverageVery low leverage limits balance-sheet debt risk and avoids substantial interest or repayment obligations while NuCana advances its pipeline. This provides greater financial flexibility than a highly indebted biotech, although it does not eliminate the need to fund ongoing operations.
Improving Loss And Cash-burn TrendThe reduction in operating cash burn and narrower recent losses indicate some progress in controlling the cost base. If sustained, better spending discipline could extend the period available to pursue clinical milestones and reduce the pace of future financing needs.
Bears Say
No Revenue GenerationNuCana remains pre-revenue, so its business has not yet demonstrated commercial demand or an operating revenue engine. Continued dependence on clinical development means future value remains tied to successful trials and eventual product approval rather than established sales.
Persistent Operating Cash BurnOngoing negative operating and free cash flow means NuCana cannot currently fund its activities from internally generated cash. This creates continuing dependence on financing to support research and development, increasing exposure to dilution or constrained investment if capital access changes.
Shrinking Equity BaseThe substantial decline in shareholders’ equity reflects cumulative value erosion from continuing losses and leaves a smaller financial base supporting the pipeline. Negative returns on equity reinforce that capital has not yet produced profitable returns, limiting resilience during extended development.
Nucana News
N040 FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was €3.20 and its highest was €7.70 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is €4.26M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Nov 12, 2026 which is in 15 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Aug 13, 2026. The company reported €0 earnings per share for the quarter.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in DE:N040
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.